Authorized purpose: ADAS 3D provides visualization, analysis, and quantification of MR and CT heart images in individual patients with cardiovascular disease, including myocardial scar assessment for pre-planning and during electrophysiology procedures.
Clinical role
Cardiac image post-processing and myocardial-scar assessment for clinical review and EP planning.
Images and patients
Radiological images; modality varies or is not specified in FDA list · Heart; myocardial scar and cardiovascular structures
Key limitation
Keep in mind: The FDA labeling states that clinical significance for arrhythmia substrate and risk stratification is not established and that the output is not an irrefutable basis or medical advice. Qualified users must interpret the results.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: ADAS 3D provides visualization, analysis, and quantification of MR and CT heart images in individual patients with cardiovascular disease, including myocardial scar assessment for pre-planning and during electrophysiology procedures.
Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Heart; myocardial scar and cardiovascular structures Input: DICOM enhanced cardiovascular MR and CT angiography images.
Who uses it?Intended users: Qualified cardiologists, electrophysiologists, radiologists, and trained technicians.
What does the software produce?Output: Visualizations and quantitative myocardial-fibrosis, cardiac-structure, and procedure-planning results exportable in supported standard formats.
What is its most important limitation?Key limitation: The FDA labeling states that clinical significance for arrhythmia substrate and risk stratification is not established and that the output is not an irrefutable basis or medical advice. Qualified users must interpret the results.
Clinical takeaway. Clinical role: ADAS 3D provides visualization, analysis, and quantification of MR and CT heart images in individual patients with cardiovascular disease, including myocardial scar assessment for pre-planning and during electrophysiology procedures.
Evidence takeaway. Evidence from the reviewed source record: K240791 FDA decision material establishes the labeled use, workflow, inputs, outputs, and limitations for ADAS 3D. No exact-submission clinical performance metric is promoted without a complete source table and version-scoped endpoint.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
ADAS 3D provides visualization, analysis, and quantification of MR and CT heart images in individual patients with cardiovascular disease, including myocardial scar assessment for pre-planning and during electrophysiology procedures.
The FDA labeling states that clinical significance for arrhythmia substrate and risk stratification is not established and that the output is not an irrefutable basis or medical advice. Qualified users must interpret the results.
K240791 FDA decision material establishes the labeled use, workflow, inputs, outputs, and limitations for ADAS 3D. No exact-submission clinical performance metric is promoted without a complete source table and version-scoped endpoint.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
K240791 FDA decision material establishes the labeled use, workflow, inputs, outputs, and limitations for ADAS 3D. No exact-submission clinical performance metric is promoted without a complete source table and version-scoped endpoint.
Do not generalize an endpoint across populations, thresholds, versions, or workflows; use only exact evidence.metrics records.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-04
Do not generalize an endpoint across populations, thresholds, versions, or workflows; use only exact evidence.metrics records.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K240791 FDA evidence package for ADAS 3D
DesignFDA 510(k) decision evidence and product verification for the exact submission.
PopulationHeart; myocardial scar and cardiovascular structures
Scopeexact submission
Tested versionADAS 3D
IndependenceSponsor or vendor study
K240791
FDA-submitted evidence for the exact decision; it is not independent clinical validation and does not establish local production qualification.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
No record matched K240791 by exact native submission identifier in the 2026-09-02 openFDA snapshot; this does not exclude product-family, later-version, or adverse-event information.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM enhanced cardiovascular MR and CT angiography images.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA package describes DICOM enhanced MR and CT input and export in industry-standard formats supported by catheter-navigation systems.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The FDA package describes stand-alone software with supported Linux and Windows operating systems; current hosting, service, security, and site configuration remain unknown.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Visualizations and quantitative myocardial-fibrosis, cardiac-structure, and procedure-planning results exportable in supported standard formats.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Visualizations and quantitative myocardial-fibrosis, cardiac-structure, and procedure-planning results exportable in supported standard formats.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The FDA package describes stand-alone software with supported Linux and Windows operating systems; current hosting, service, security, and site configuration remain unknown.
Use by qualified cardiologists, electrophysiologists, radiologists, and trained technicians. Follow the exact labeling, local training, supervision, and escalation requirements.
The FDA package describes stand-alone software with supported Linux and Windows operating systems; current hosting, service, security, and site configuration remain unknown.
Monitor labeling, software version, complaints, recalls, failed inputs, overrides, and postmarket signals against the exact submission and installed configuration.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
27Fields reviewed
11Source classes checked
20Screened PubMed leads
6Screened trial leads
0Unreviewed FDA recall leads
No evidence was promoted. Two PubMed records name ADAS 3D but do not identify the tested software version or K240791; the remaining records are generic cardiac-imaging evidence, other products, or unlinked trials. The current discovery snapshot contains 20 PubMed and 6 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price or commercial contract for the exact submission and version was identified.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission
No exact-product payer coverage or reimbursement determination was identified in reviewed public material.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not publicly available - checked 2026-09-04 - Exact FDA submission
Public materials reviewed for this exact submission do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.
Authorized purpose: ADAS 3D supports visualization and analysis of MR and CT images of the heart for individual patients with cardiovascular disease, including patients with myocardial scar from ischemic or non-ischemic heart disease. Qualified professionals may use it for cardiac calculation, quantification, visualization, pre-planning, and electrophysiology procedures; produced data support clinical decision-making and must not be used as irrefutable medical advice or for radiotherapy planning, dose calculation, or treatment delivery.
Modality
Radiological images; modality varies or is not specified in FDA list
Authorized purpose: MI View&GO is a medical diagnostic application for viewing, manipulating, quantifying, analyzing, and comparing PET, nuclear-medicine, CT, and MR images across one or more time points, including labeled oncology, cardiology, neurology, organ-function, and radiotherapy-planning workflows.
Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Whole body, organs, tumors, heart, brain, and oncology regions
Authorized purpose: Imagine Enterprise Suite receives, stores, shares, visualizes, quantifies, and processes images from multiple modalities; MPXA-2000 supports coronary-angiography calculation with automated vessel contours that require review and editing.
Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Cardiac and coronary anatomy plus multi-modality clinical studies
3mensio Workstation is standalone medical-image analysis software for advanced visualization and quantitative analysis of cardiovascular structures. It supports CT, X-ray angiography, and two- and three-dimensional ultrasound DICOM data for planning and sizing cardiovascular interventions, postoperative evaluation, coronary measurements, and calcium scoring.
Modality
Radiological images; modality varies or is not specified in FDA list
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.